Immunovant Inc. (IMVT)
Market Closed
3 Jun, 20:00
NASDAQ (NGS) NASDAQ (NGS) Primary $
31. 15
+0.23
+0.74%
$
6.86B Market Cap
- P/E Ratio
- Div Yield
1,850,851 Volume
-1.77 Eps
$ 30.92
Previous Close 
Want to track IMVT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Top 2 Health Care Stocks That May Collapse This Quarter
As of Sept. 9, 2024, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Benzinga | 1 year ago
Why Is Immunovant (IMVT) Up 13.8% Since Last Earnings Report?
Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock?
Zacks | 1 year ago
Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus
Immunovant (IMVT) declines 5% on dismal fourth-quarter fiscal 2024 results. The company names IMVT-1402 as its new lead candidate to initiate several studies for autoimmune indications.
Zacks | 2 years ago
Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump
Biohaven stock crashed Wednesday after the company's experimental protein-degrading drug lagged investor expectations.
Investors | 2 years ago
